| Sex | Gl (n=20) | G2 (n=97) |
|---|---|---|
| Male | 5 (25%) | 32 (33%) |
| Female | 15 (75%) | 65 (67%) |
| Age | ||
| Range | 23–40 | 41–80 |
| Median | 36 | 55 |
| Duration of symptoms (months) | ||
| Range | 1–100 | 1–150 |
| Median | 4 | 6 |
| Sex | Gl (n=20) | G2 (n=97) |
|---|---|---|
| Male | 5 (25%) | 32 (33%) |
| Female | 15 (75%) | 65 (67%) |
| Age | ||
| Range | 23–40 | 41–80 |
| Median | 36 | 55 |
| Duration of symptoms (months) | ||
| Range | 1–100 | 1–150 |
| Median | 4 | 6 |